{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:04:01Z","timestamp":1773281041217,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T00:00:00Z","timestamp":1521417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"crossref","award":["#3840"],"award-info":[{"award-number":["#3840"]}],"id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ajoc.2018.03.018","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T20:34:46Z","timestamp":1521578086000},"page":"264-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Adrenocorticotropic hormone analogue as novel treatment regimen in ocular cicatricial pemphigoid"],"prefix":"10.1016","volume":"10","author":[{"given":"Yael","family":"Sharon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9863","key":"10.1016\/j.ajoc.2018.03.018_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"issue":"4-5","key":"10.1016\/j.ajoc.2018.03.018_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/08820538.2011.588660","article-title":"Ocular cicatricial pemphigoid: a Review of clinical features, immunopathology, differential diagnosis, and current management","volume":"26","author":"Kirzhner","year":"2011","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ajoc.2018.03.018_bib3","first-page":"527","article-title":"Cicatricial pemphigoid","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"12","key":"10.1016\/j.ajoc.2018.03.018_bib4","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2008.08.002","article-title":"Treatment of ocular mucous membrane pemphigoid with immunosuppressive Drug therapy","volume":"115","author":"Thorne","year":"2008","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajoc.2018.03.018_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2007.04.027","article-title":"Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes","volume":"115","author":"Saw","year":"2008","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajoc.2018.03.018_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2147\/TCRM.S1140","article-title":"Treatment strategies in mucous membrane pemphigoid","volume":"4","author":"Neff","year":"2008","journal-title":"Therapeut Clin Risk Manag"},{"issue":"3","key":"10.1016\/j.ajoc.2018.03.018_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.survophthal.2015.12.007","article-title":"Update on ocular cicatricial pemphigoid and emerging treatments","volume":"61","author":"Queisi","year":"2016","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajoc.2018.03.018_bib8","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.ophtha.2003.11.012","article-title":"Intravenous immunoglobulin therapy in patients with Ocular\u2013Cicatricial pemphigoid","volume":"111","author":"Sami","year":"2004","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajoc.2018.03.018_bib9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajoc.2018.03.018_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.smim.2015.02.003","article-title":"ACTH: the forgotten therapy","volume":"27","author":"Montero-Melendez","year":"2015","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/j.ajoc.2018.03.018_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.06.022","article-title":"Targeting melanocortin receptors as potential novel therapeutics","volume":"111","author":"Getting","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ajoc.2018.03.018_bib12","series-title":"Acthar Gel (Repository Corticotropin Injection)","author":"Full Prescribing Information HP","year":"2015"},{"issue":"9","key":"10.1016\/j.ajoc.2018.03.018_bib13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/0961203314532562","article-title":"Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial","volume":"23","author":"Fiechtner","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.ajoc.2018.03.018_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/DDDT.S19331","article-title":"Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial","volume":"5","author":"Simsarian","year":"2011","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.ajoc.2018.03.018_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12882-016-0241-7","article-title":"Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series","volume":"17","author":"Madan","year":"2016","journal-title":"BMC Nephrol"},{"issue":"3","key":"10.1016\/j.ajoc.2018.03.018_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1542\/peds.97.3.375","article-title":"High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study","volume":"97","author":"Baram","year":"1996","journal-title":"Pediatrics"},{"key":"10.1016\/j.ajoc.2018.03.018_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/DDDT.S33110","article-title":"Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series","volume":"6","author":"Levine","year":"2012","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.ajoc.2018.03.018_bib18","first-page":"527","article-title":"Cicatricial pemphigoid","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"6","key":"10.1016\/j.ajoc.2018.03.018_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.preteyeres.2004.05.005","article-title":"Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment","volume":"23","author":"Ahmed","year":"2004","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"10.1016\/j.ajoc.2018.03.018_bib20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0161-6420(90)32479-X","article-title":"Cicatricial pemphigoid and erythema multiforme","volume":"97","author":"Mondino","year":"1990","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajoc.2018.03.018_bib21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/bjo.80.4.292","article-title":"Progression of disease in ocular cicatricial pemphigoid","volume":"80","author":"Elder","year":"1996","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajoc.2018.03.018_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2007-0027","article-title":"\u03b1-Melanocyte-Stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases","volume":"29","author":"Brzoska","year":"2008","journal-title":"Endocr Rev"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993617302918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993617302918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:57:55Z","timestamp":1762527475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993617302918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":22,"alternative-id":["S2451993617302918"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2018.03.018","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adrenocorticotropic hormone analogue as novel treatment regimen in ocular cicatricial pemphigoid","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2018.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}